Adare Pharma Solutions

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

An interview with Tom Sellig the Chief Executive Officer of Adare Pharma Solutions at the CPHI Conference in Frankfurt, Germany.

DuraGran® reduces the excipients and/or steps to build beads or granules, and at higher concentrations, spheronization and extrusion steps typically used can be forgoed.

Thursday, September 30, 2021 at 1pm EDT| 12pm CDT| 10am PDT Formulating drugs to facilitate patient adherence, especially for pediatrics, is an ongoing industry challenge. Learn about challenges encountered when formulating drugs with a patient-centric focus, clinical recommendations for pediatric dosage forms, repurposing strategies for formulation development, and technology platforms to optimize oral dosage forms.

Multiparticulate systems have several advantages over conventional tablet or capsule formulations. Download this whitepaper to learn more.

Multiparticulate systems have several advantages over conventional tablet or capsule formulations. Download this whitepaper to learn more.

In pharma delivery, size matters. So, too, do the intricacies of dosage format, active ingredient compatibility, and effective delivery to patients—whatever their needs or preferences may be. Yet standard dosage forms haven’t always provided companies the options, flexibility, or performance to bring all those puzzle pieces together during therapeutic development. We spoke with Nathan H. Dormer, PhD, Director of Drug Product Development at Adare Pharma Solutions, to learn how this new technology platform is expanding the frontiers of therapeutic delivery and improving patients’ experience in the process.

As the industry—and the world—faces unprecedented challenges, your choice of CDMO plays an increasingly important role in the success of your project. New formulations and underserved patient populations demand a level of expertise many development and manufacturing partners simply don’t have. Is your CDMO partner able to adapt to today’s ever-changing world? Giovanni Ortenzi, the leader of Adare Pharma’s global pharmaceutical development and technical services, was recently interviewed about how Adare is uniquely qualified to meet and overcome these new challenges. Adare’s unique mix of expertise, innovation, and capacity makes us the perfect choice to bring your new project to market.

A variety of microencapsulation techniques are widely used in the pharmaceutical industry including fluid bed coating, spray drying, solvent evaporation, and more. However, one method—coacervation—offers several unique benefits to developers interested in working with challenging and/or bitter-tasting molecules, managing a product’s lifecycle, and accelerating development timelines. Learn how Adare’s Microcaps® taste masking technology platform, utilizes the coacervation process to solve your formulation challenges.

The Parvulet TM Technology enables the conversion of powders or tablets to a soft food like texture, ideal for pediatric and geriatric patients.